Topotarget and Spectrum Pharmaceuticals, a big biotech comapny, announce an amendment to the companies’ existing pharma licensing agreement.
Pursuant to the pharma licensing amendment, Spectrum Pharmaceuticals will carry the responsibility for the commercial manufacture of belinostat for a 5-year period with the possibility of renewal.
In collaboration, Topotarget and Spectrum Pharmaceuticals have made an amendment to the License Agreement dated February 2, 2010.
The amendment entails a shift from Topotarget to Spectrum in the area of world-wide clinical, commercial, and Named Patient product supply.
Henceforward, Spectrum carries the responsibility for the future manufacture of belinostat for all territories.
The pharma licensing agreement has a term of 5 years with possibility for prolongation; alternatively Topotarget may, at its own choice, take over the responsibility of manufacturing belinostat in Topotarget’s commercial territory.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Partnering Deals and Alliances with Big Biotech
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity